Crossmark

Targeting breast cancer stem cells in ER-positive breast cancer by repurposing the benzoporphyrin derivative verteporfin as a YAP/TAZ small molecule inhibitor

Crossref DOI link: https://doi.org/10.1007/s11033-025-10264-1

Published Online: 2025-01-24

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Talukdar, Priyanka Dey https://orcid.org/0009-0008-1005-8069
Roy, Himansu

Chatterji, Urmi https://orcid.org/0000-0002-9317-5672
Funding

Funding for this research was provided by:

Department of Science and Technology and Biotechnology, GoWB, India (140(Sanc.)-BT/P/Budget/RD-75/2017)
License Information

Text and Data Mining valid from 2025-01-24

Version of Record valid from 2025-01-24
More Information

Article History

Received: 6 December 2024

Accepted: 14 January 2025

First Online: 24 January 2025

Declarations

:

: The study was approved by the Institutional Review Board and the Human Ethical Committee of the Department of Surgery, Medical College, Kolkata, India (MC/KOL/IEC/NON-SPON/204/12-2015).

: Written informed consent was obtained from the parents or close relatives.

: The authors affirm that no individual person’s data in any form has been included in the manuscript.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below